Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Sernova ( (TSE:SVA) ).
Sernova Biotherapeutics has announced a positive update on its Phase 1/2 clinical trial for the Cell Pouch Bio-hybrid Organ aimed at treating type 1 diabetes. The Data and Safety Management Board has approved the enrollment of the final patient in Cohort B, and Sernova is preparing to advance to Cohort C in the second half of 2025. The trial’s primary endpoint is to demonstrate the safety and tolerability of islet transplantation into the Cell Pouch. The ongoing trial has shown promising results, including islet cell survival and insulin independence in patients, with no evidence of detrimental fibrosis. Sernova plans to collaborate with Evotec to launch a T1D trial using induced pluripotent stem cell islet-like clusters following the conclusion of Cohort C.
More about Sernova
Sernova Biotherapeutics is a clinical-stage company specializing in regenerative medicine therapeutics. It focuses on developing its Cell Pouch Bio-hybrid Organ, which combines human donor cells or stem-cell derived islet-like clusters to treat type 1 diabetes (T1D) and thyroid disorders. The company’s innovative approach aims to replace the function of compromised organs with a Bio-hybrid Organ, initially targeting chronic diseases such as T1D.
YTD Price Performance: -32.61%
Average Trading Volume: 148,865
Technical Sentiment Signal: Buy
Current Market Cap: C$49.27M
For a thorough assessment of SVA stock, go to TipRanks’ Stock Analysis page.